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Table 1. Demographics and Baseline Characteristics (ITT Population)
Control
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Table 2. Summary of Proportion of Patients With CR 
(0–120 h) in Cycle 1 (MITT Population)
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Table 4. Adverse Events Possibly Related to Study Treatment Reported in >1% 
of Patients in Any Treatment Group in Any Cycle (Safety Population)
Treatment Groups
Single Oral
2.02
[1.53, 2.68]
1.98
[1.50, 2.61]
3-Day Oral
2.05
[1.55, 2.7]
3-Day IV/OralDose
Odds ratio
[98.3% Cl]
Table 3. Probability of CR During Any MEC Cycle With 
Casopitant Compared With No Casopitant
•  Chemotherapy-induced nausea and 
vomiting (CINV) associated with 
anthracycline-cyclophosphamide (AC), 
frequently used to treat breast cancer, 
is considered to be among the most 
difﬁcult CINV to prevent
• Casopitant is a potent and selective 
neurokinin 1 receptor antagonist that is 
currently in development for prevention 
of CINV and postoperative nausea and 
vomiting. Phase II1 and phase III2,3 trials 
have evaluated the safety and efﬁcacy 
of casopitant added to a 2-drug 
(ondansetron and dexamethasone) 
antiemetic regimen in patients receiving 
moderately or highly emetogenic 
chemotherapy (MEC or HEC)
•  A phase III study performed in patients
 receiving MEC (primarily AC) 
demonstrated a signiﬁcant beneﬁt with 
single oral, 3-day oral, and 3-day 
intravenous (IV)/oral casopitant added 
to ondansetron plus dexamethasone 
during the ﬁrst cycle of chemotherapy.3 
This poster reports the results of a post 
hoc analysis of data from the multiple-
 cycle extension of the study
Study Design
• Phase III, multinational, multicentre,
 randomised, double-blind, active-
controlled, 4-arm, parallel-group study
Figure 1. Study Schematic 
*All patients received ondansetron 8 mg oral twice daily on Days 1-3 and a single
dose of dexamethasone 8 mg IV on Day 1. Follow-up for safety was at
least through end of cycle.
Patients
• Chemotherapy-naïve subjects ≥18 
years of age diagnosed with a 
malignant solid tumour and scheduled 
to receive 1 of the following AC 
regimens were eligible.
  — Regimen 1: cyclophosphamide IV
   (500–1500 mg/m2) and       
  doxorubicin IV (≥40 mg/m2)
  — Regimen 2: cyclophosphamide IV
   (500–1500 mg/m2) and epirubicin  
  IV (≥ 60 mg/m2)
• Additional agents of low or minimal
 emetogenic potential could be added.
METHODS
Statistical Analyses
•  Primary endpoint
  — Percentage of patients with    
   complete response (CR) (no   
   vomiting/retching, and no     
   rescue therapy) during the first  
   120 hours following the initiation  
   of their first cycle of MEC regimen
•  Secondary endpoints
  — CR during first 120 hours for   
   cycles 2, 3, and 4
•  No formal testing was provided for 
these analyses
•  A subject diary was used to record 
efficacy data (including emesis, 
nausea, and rescue medications) 
during the 120-hour assessment
 phase of each cycle of chemotherapy
•  Need for antiemetic rescue medication 
(any drug taken specifically for nausea 
and/or emesis) during the 120-hour 
assessment period was considered a 
treatment failure
Patient Disposition
•  Patient demography
  — Generally balanced across the 4
    treatment groups for the ITT   
   population
  — 98% were female and      
   95%–97% had a diagnosis of   
   breast cancer
  — Overall, 96% of participants    
   completed cycle 1 of treatment and  
   76% completed all planned cycles
Efficacy in Cycle 1
•  Casopitant added to standard 
antiemetic therapy significantly 
increased the percentage of patients 
who achieved a CR in cycle 1 for all 3 
dosing regimens
Abbreviations: CI, confidence interval; CMH, Cochran-Mantel-Haenszel.
Persistent Efficacy in Cycles 2, 3, and 4
•  Improved efficacy persisted over 4 cycles 
for all 3 casopitant dosing regimens
Figure 2. Proportion of Subjects 
With CR (0–120 h) for Each of 4 
Cycles of MEC (MITT Population)
Abbreviations: MEC, moderately emetic chemotherapy; MITT, modified
intent-to-treat.
Efficacy in Any Cycle
Casopitant Was Well Tolerated
Abbreviation: ALT, alanine aminotransferase.
No significant differences were seen between the control arm and the study arms.
•  Casopitant added to ondansetron 
plus dexamethasone consistently 
increased overall CR (0–120) rates 
over repeated chemotherapy cycles
•  No difference in protection from nausea 
was seen during multiple cycles
•  Casopitant was well tolerated across 
all cycles
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